PMID- 20719167
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20100819
IS  - 1999-6187 (Electronic)
IS  - 1009-3419 (Linking)
VI  - 12
IP  - 8
DP  - 2009 Aug 20
TI  - Gene Polymorphisms and Chemotherapy in Non-small Cell Lung Cancer.
PG  - 837-40
LID - 10.3779/j.issn.1009-3419.2009.08.01 [doi]
AB  - The phamacogenetics is being used to predict whether the selected chemotherapy 
      will be really effective and tolerable to the patient. Irinotecan, oxidized by 
      CYP3A4 to produce inactive compounds, is used for treatment of various cancers 
      including advanced non small cell lung cancer (NSCLC) patients. CYP3A4(*)16B 
      polymorphism was associated with decreased metabolism of irrinotecan. Irinotecan 
      is also metabolized by carboxylesterase to its principal active metabolite, 
      SN-38, which is subsequently glucuronidated by UGT1As to form the inactive 
      compound SN-38G. UGT1A1(*)28 and UGT1A1(*)6 polymorphisms were useful for 
      predicting severe toxicity with NSCLC patients treated with irinotecan-based 
      chemotherapy. Platinum-based compounds (cisplatin, carboplatin) are being used in 
      combination with new cytotoxic drugs such as gemcitabine, paclitaxel, docetaxel, 
      or vinorelbine in the treatment of advanced NSCLC. Cisplatin activity is mediated 
      through the formation of cisplatin-DNA adducts. Gene polymorphisms of DNA repair 
      factors are therefore obvious candidates for determinants of repair capacity and 
      chemotherapy efficacy. ERCC1, XRCC1 and XRCC3 gene polymorphisms were a useful 
      marker for predicting better survival in advanced NSCLC patients treated with 
      platinum-based chemotherapy. XPA and XPD polymorphisms significantly increased 
      response to platinum-based chemotherapy. These DNA repair gene polymorphisms were 
      useful as a predictor of clinical outcome to the platinum-based chemotherapy. 
      EGFR kinase inhibitors induce dramatic clinical responses in NSCLC patients with 
      advanced disease. EGFR gene polymorphism in intron 1 contains a polymorphic 
      single sequence dinucleotide repeat (CA-SSR) showed a statistically significant 
      correlation with the gefitinib response and was appeared to be a useful 
      predictive marker of the development of clinical outcome containing skin rashes 
      with gefitinib treatment. The other polymorphisms of EGFR were also associated 
      with increased EGFR promoter activity. EGFR gene mutations and polymorphisms were 
      also associated with EGFR kinase inhibitors response and toxicity.
FAU - Osawa, Kayo
AU  - Osawa K
AD  - Faculty of Health Sciences, Kobe University Graduate School of Health Sciences, 
      7-10-2, Tomogaoka, Suma-ku, Kobe, 654-0142, Japan. osawak@kobe-u.ac.jp.
LA  - eng
PT  - Editorial
PL  - China
TA  - Zhongguo Fei Ai Za Zhi
JT  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
JID - 101126433
EDAT- 2010/08/20 06:00
MHDA- 2010/08/20 06:01
CRDT- 2010/08/20 06:00
PHST- 2010/08/20 06:00 [entrez]
PHST- 2010/08/20 06:00 [pubmed]
PHST- 2010/08/20 06:01 [medline]
AID - 10.3779/j.issn.1009-3419.2009.08.01 [doi]
PST - ppublish
SO  - Zhongguo Fei Ai Za Zhi. 2009 Aug 20;12(8):837-40. doi: 
      10.3779/j.issn.1009-3419.2009.08.01.